BioLight announced on promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect® technology. The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.
BioLight announced today that it has obtained the worldwide rights (excluding Israel and Italy) for the manufacturing, distribution, marketing and sales of a groundbreaking new eye drop product for the treatment of dry eye syndrome (DES) and other ophthalmic indications.
BioLight Life Sciences reported operational and financial results for the year ended December 31, 2015. Results were characterized by continued development and commercial progress in multiple markets, and the achievement of all previously announced 2015 milestones.
- Completed an upsized private investment and signed a strategic partnership with …
BioLight today announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering. The number of the securities to be offered and the price range for the proposed offering have not yet been determined. …
BioLight announced today the completion of a successful U.S. clinical study that was designed to assess the effectiveness of its TeaRx™ multi-assay test in evaluating tears’ components of healthy subjects as well as of patients suffering from dry eye syndrome.
BioLight announced today that following its announcement on November 25, 2015 of BioLight’s IOPtima Ltd. subsidiary regarding entering into a joint financing agreement with two Asia-based venture capital firms, according to which the New Investors will invest an aggregate amount of US$6.0 million in consideration for the issuance of approximately …
BioLight announced today that its IOPtiMate™ system for the treatment of glaucoma has been approved by the Canadian Medical Devices Bureau, allowing the Company to commercialize the surgical system in Canada.
BioLight announced the first sale of the IOPtiMate™ system to a medical center located in Portugal.
BioLight today reported operational and financial results for the third quarter ended September 30, 2015.
- Reported first IOPtiMate™ System sales and additional distribution agreements, both in new territories.
- Completed enrollment into the second U.S. clinical study in which TeaRx’s effectiveness is being assessed in tears …
BioLight announced today that its cancer diagnostics subsidiary, Micromedic Technologies, has entered into a Collaboration Agreement with Axella Research LLC, to advance the clinical and regulatory efforts required to commercialize the CellDetect® non-invasive diagnostic test for the monitoring of bladder cancer recurrence in the United States.